More recently, an analysis of a French registry cohort showed an incidence of BTK mutations of 57% in patients who were still responding to ibrutinib, suggesting that a substantial proportion of CLL patients receiving ibrutinib monotherapy already have resistance-mediating mutations though still responding clinically to treatment [42]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.